Renuka Iyer

Medical Oncology
2022 Buffalo Spree Top Docs badge

Dr. Iyer is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2022

Specializing In:

Bile duct cancer Cholangiocarcinoma Hepatocellular cancer Neuroendocrine cancer

Special Interests:

Develop novel therapies for rare cancer Immunotherapy

About Renuka Iyer


Roswell Park Comprehensive Cancer Center

  • Professor of Oncology
  • Co-Director, Liver and Pancreas Tumor Center
  • Section Chief for Gastrointestinal Oncology

Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo

  • Professor of Medicine


Education and Training:

  • 1998 - MD - Grant Medical College, University of Mumbai, Maharashtra, India


  • 1998-2001 - Resident - Internal Medicine, Lincoln Medical and Mental Health Center and Cornell University School of Medicine, Bronx, NY
  • 1997-1998 - Postdoctoral Associate- Fox Chase Cancer Center, Philadelphia, PA


  • 2001-2004 - Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY

Board Certification:

  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Professional Memberships:

  • Cholangiocarcinoma Foundation
  • Cholangiocarcinoma Foundation - Medical Advisory Board
  • Cholangiocarcinoma Foundation - Nursing Advisory Board
  • NANETs
  • NANETs - Regional Conference Committee Chair
  • Hepatobiliary Cancer Panel, National Comprehensive Cancer Network
  • American Association for Cancer Research
  • NET Physician/Expert
  • American Association for the Study of Liver Diseases
  • American College of Gastroenterology
  • American College of Surgeons Oncology Group
  • American Society of Clinical Oncology

Honors & Awards:

  • June 2018 - Best Teacher Award, Awarded by Roswell Park Comprehensive Cancer Center Medical Oncology Fellows
  • June 2008 - Best Teacher Award, Awarded by Roswell Park Comprehensive Cancer Center Medical Oncology Fellows
  • January 2008 - American Cancer Society Scholar Award
  • November 2007 - EORTC-NCI-ASCO Molecular Markers Development Workshop, Brussels, Belgium
  • April 2003 - Thomas Frawley Resident Research Fellowship award, by State University of New York at Buffalo
  • July 2002 - ASCO-AACR Methods in Clinical Cancer Research Workshop, Vail, CO
  • October 1997 - Junior Investigator Award by the Executive Committee of the Tenth International Conference on Chemical Modifiers in Cancer Treatment


Research Overview:

Research interests in phase 1 and 2 clinical trials in GI cancer and animal models research of liver cancer.

Clinical Trials

Featured on Cancer Talk


Full Publications list on PubMed
  • Kalathil SG, Lugade AA, Miller A, Iyer R, Thanavala Y. PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. JCI Insight. 2016 Jul 21;1(11):e86182. doi: 10.1172/jci.insight.86182. PMID: 27540594; PMCID: PMC4986927.
  • Kalathil SG, Lugade AA, Iyer R, Miller A, Thanavala Y. Endothelial progenitor cell number and ERK phosphorylation serve as predictive and prognostic biomarkers in advanced hepatocellular carcinoma patients treated with sorafenib. Oncoimmunology. 2016 Sep 20;5(10):e1226718. doi: 10.1080/2162402X.2016.1226718. PMID: 27853648; PMCID: PMC5087301.
  • Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013 Apr 15;73(8):2435-44. doi: 10.1158/0008-5472.CAN-12-3381. Epub 2013 Feb 19. PMID: 23423978; PMCID: PMC3645275.